- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/14 - Radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 215/14
Total number of patents in this class: 465
10-year publication summary
|
43
|
28
|
31
|
39
|
34
|
33
|
25
|
21
|
16
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4880 |
22 |
| Gilead Sciences, Inc. | 2032 |
19 |
| Merck Patent GmbH | 5815 |
8 |
| Merck Sharp & Dohme LLC | 3751 |
8 |
| Janssen Pharmaceutica N.V. | 3394 |
7 |
| Santen Pharmaceutical Co., Ltd. | 600 |
7 |
| Novartis AG | 10744 |
6 |
| Neurocrine Biosciences, Inc. | 426 |
6 |
| Nissan Chemical Industries, Ltd. | 1711 |
6 |
| Centre National de La Recherche Scientifique | 10464 |
5 |
| Agios Pharmaceuticals, Inc | 216 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 875 |
5 |
| University College Dublin, National University of Ireland, Dublin | 360 |
5 |
| Allergan, Inc. | 2347 |
4 |
| Alkermes Pharma Ireland Limited | 270 |
4 |
| API Corporation | 225 |
4 |
| Ardelyx, Inc. | 115 |
4 |
| Cadila Healthcare Limited | 317 |
4 |
| Imago Biosciences, Inc. | 38 |
4 |
| Toyama Chemical Co., Ltd. | 102 |
4 |
| Other owners | 328 |